Monjuvi Combination Shows Promise in Reducing Non-Hodgkin Lymphoma Progression
The 899-patient trial also improved event-free survival and kept R-CHOP delivery intact, researchers reported at ASCO.
- Combining Tafasitamab and Revlimid with R-CHOP extended progression-free survival in patients with newly diagnosed high-risk DLBCL or HGBL, according to data from the phase III frontMIND trial involving 899 patients.
- For more than 2 decades, R-CHOP has been the global standard for DLBCL, yet about 40% of patients—particularly those with high-risk disease—are not cured with first-line therapy, prompting the need for improved treatments.
- At a median follow-up of 35.2 months, Incyte Pharmaceuticals' Monjuvi combined with Revlimid reduced disease progression risk by 25% compared to R-CHOP alone, though 25.7% of combination-treated patients discontinued due to adverse events versus 17.9% in the control group.
- Following these results, the FDA approved the combination for untreated DLBCL or HGBL. The POLARIXopens trial separately showed that substituting Polivy for vincristine in R-CHOP also significantly improved progression-free survival.
- Incyte aims to expand the drug's application as a first-line treatment for newly diagnosed patients, a move that could potentially double the currently eligible patient population for this therapy.
11 Articles
11 Articles
Monjuvi Combination Shows Promise in Reducing Non-Hodgkin Lymphoma Progression
Incyte's Monjuvi, when used with a multi-drug regimen including Revlimid and R-CHOP, reduces the progression of aggressive non-Hodgkin lymphoma by 25% over standard treatment alone. However, the combination also leads to a higher rate of severe adverse events and study dropouts. Incyte plans to expand approval for its use as an initial treatment.
Frontline Targeted Therapies Plus R-CHOP Boosts PFS in High-Risk B-Cell Lymphomas
(MedPage Today) -- CHICAGO -- Combining two targeted therapies with standard-of-care chemotherapy extended progression-free survival (PFS) in patients with newly diagnosed B-cell lymphomas, according to data from the frontMIND trial. In the...
Incyte's Monjuvi combo cuts DLBCL progression risk 25% but raises side effects rate
Incyte's Monjuvi as part of a multi-drug regimen that includes a chemotherapy standard of care for an aggressive form of non-Hodgkin lymphoma reduced the risk of disease progression, relapse or death by 25% compared to the standard alone, but with a higher rate of study dropouts due to side effects.The company, which first announced the data in January, said it would have overall survival data for the drug combination at a later date. Pablo Cag…
Hastings Tribune
Rutland HeraldIncyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL
WILMINGTON, Del.--(BUSINESS WIRE)--May 30, 2026-
Coverage Details
Bias Distribution
- 71% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
